Wall Street analyst estimates for Definium Therapeutics, Inc. (DFTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD).
Consensus price target
$67.45 (+89 % vs price $35.68)
between $52.00 and $79.00 · 10 targets published in the last quarter
Closing price, Oct 28
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $-3.20 | 14 | ||
| 2027E | $29.3M | $6.8M – $137M | $-2.05 | 12 |
| 2028E | $271M | $36.3M – $1.4B | $-0.86 | 13 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 12 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (−2 sell to +2 buy) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.56 | ||
| 2026-08-06 | $-1.44 | $-0.54 | -166.2% |
| 2026-05-07 | $-0.71 | $-0.47 | -51.1% |
| 2026-02-26 | $-0.51 | $-0.48 | -5.4% |
| 2025-11-06 | $-0.78 | $-0.52 | -50.0% |
| 2025-07-31 | $-0.50 | $-0.38 | -31.6% |
| 2025-05-08 | $-0.35 | $-0.36 | +2.8% |
| 2025-03-06 | $-0.41 | $-0.33 | -24.2% |
Valuation Ratios
| Price / Book | 4.59 |
| EV / EBITDA | -13.25 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $5,501 | $6,682 | $6,684 | 0 | 0 | 0 | $3.2M | $527,000 | 0 |
| Gross Profit | 0 | -$5,501 | -$6,682 | -$6,684 | 0 | 0 | 0 | -$3.2M | -$527,000 | 0 |
| Research & Development | 0 | 0 | 0 | 0 | $18.6M | $34.8M | $36.2M | $49.0M | $65.3M | $117.7M |
| Selling, General & Admin | $111,252 | $1.2M | $855,262 | $461,501 | $14.4M | $59.1M | $30.2M | $41.7M | $38.6M | $48.6M |
| Operating Expenses | $111,252 | $1.2M | $855,262 | $461,501 | $33.0M | $93.9M | $66.3M | $90.7M | $103.4M | $166.3M |
| Operating Income | -$111,250 | -$1.2M | -$861,940 | -$468,180 | -$33.0M | -$93.9M | -$66.3M | -$93.9M | -$103.9M | -$166.3M |
| EBITDA | -$111,250 | -$1.5M | -$851,262 | -$1.1M | -$33.2M | -$91.2M | -$52.1M | -$92.6M | -$105.9M | -$178.3M |
| Interest Expense | 0 | 0 | 0 | 0 | $164,000 | $359,000 | $1.5M | $920,000 | $2.3M | $5.5M |
| Pre-tax Income | -$179,900 | -$1.2M | -$857,944 | -$1.1M | -$33.9M | -$94.2M | -$56.8M | -$95.7M | -$108.7M | -$183.8M |
| Income Tax | 0 | -$2 | -$2 | -$4 | 0 | -$1.2M | 0 | 0 | 0 | 0 |
| Net Income | -$179,900 | -$1.2M | -$857,944 | -$1.1M | -$34.1M | -$93.0M | -$56.8M | -$95.7M | -$108.7M | -$183.8M |
| EPS | $-2.24 | $-4.85 | $-2.74 | $-2.94 | $-1.92 | $-3.40 | $-1.53 | $-2.44 | $-1.54 | $-2.06 |
| EPS (Diluted) | $-2.24 | $-4.85 | $-2.74 | $-2.94 | $-1.92 | $-3.40 | $-1.53 | $-2.44 | $-0.15 | $-2.06 |
| Shares Outstanding (Diluted) | 80,416 | 252,818 | 312,548 | 379,411 | 17.7 M | 27.4 M | 30.9 M | 39.2 M | 704.6 M | 89.3 M |
Price
| Price | $35.68 (closing price, October 28, 2026) |
| Market Cap | $4.8B |
| Exchange | NASDAQ |
| Country | US |
Related companies: AXSM · PRAX · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX
Explore sector: Healthcare · Biotechnology
More sections of DFTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks